Document:

exv10w22

Exhibit 10.22

Henry Schein, Inc.

135 Duryea Road

Melville, New York 11747

December 23, 2008

Biolase Technology, Inc.

4 Cromwell

Irvine, California 92618

Attention: David M. Mulder

Dear Mr. Mulder:

     With reference to that certain License and Distribution Agreement by and between Henry Schein,
Inc. (the “Distributor”) and Biolase Technology, Inc. (the “Company”), dated as of August 8, 2006
and subsequently amended by Addendum I, effective as of April 1, 2007, and by the Amendment dated
as of February 29, 2008 (collectively, the “Agreement”), the Distributor and the Company hereby
agree that the initial term under the Agreement shall be extended to December 31, 2010.

     This letter agreement shall be governed by, and construed and enforced in accordance with the
laws of the State of California, without regard to conflict of laws principles.

Very truly yours,

HENRY SCHEIN, INC.

By: /s/ Brian S. Watson

           Name: Brian S. Watson

           Title: Vice President, Strategic and Business Planning

ACCEPTED AND AGREED:

BIOLASE TECHNOLOGY, INC.

By: /s/ David M. Mulder

           Name: David M. Mulder

           Title: Chief Financial Officerexv10w28

Exhibit 10.28

SETTLEMENT AGREEMENT

     This Settlement Agreement (“Agreement”) is entered by and between the Diodem Group and the
Biolase Parties and effective as of this 30th day of September, 2008 (the “Effective
Date”).

RECITALS

     A. Diodem, Biolase, and BL Acquisition II entered into a Definitive Asset Purchase Agreement
and certain ancillary agreements dated and effective as of January 24, 2005, in settlement of a
prior patent litigation between Diodem and Biolase that was litigated in the United States District
Court for the Central District of California and captioned Diodem, LLC. V. Lumenis, Ltd., et al.
Case No. CV 03-2142 GAF (RCx) (the “Patent Lawsuit”);

     B. On February 22, 2008, Diodem filed a lawsuit against Biolase and BL Acquisition II in the
Superior Court of California for the County of Los Angeles, alleging that Biolase and BL
Acquisition II breached the Definitive Agreement and the ancillary Registration Rights Agreement.
The lawsuit is captioned Diodem v. Biolase Technology, Inc. et al. Case No. BC 385794 (the
“Contract Lawsuit”). Biolase and BL Acquisition II have denied the allegations of Diodem’s
complaint and further contend that Diodem does not have standing to assert certain claims made in
the lawsuit;

     C. On August 21, 2008, the parties participated in a mediation in an attempt to resolve the
claims asserted in the Contract Lawsuit and reached agreement on the principle terms of a
settlement. This Agreement sets forth the terms agreed to by the parties in their mutual effort
and desire to comprise and settle all claims relating to the Contract Lawsuit.

AGREEMENT

     NOW THEREFORE, in consideration of the foregoing, the mutual promises and covenants herein
contained and other valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties to this Agreement agree as follows:

1. DEFINITIONS

     “Biolase” means Biolase Technology, Inc., a Delaware corporation.

     “BL Acquisition II” means BL Acquisition II, Inc., a Delaware corporation.

     “Biolase Parties” means Biolase and BL Acquisition II.

 - 1 - 

 

     “Definitive Agreement” means the Definitive Asset Purchase Agreement entered by Diodem,
Biolase, and BL Acquisition II on January 24, 2005, and its schedules, exhibits, and attachments.

     “Registration Rights Agreement” means the agreement by that name entered by Diodem and Biolase
on January 24, 2005.

     “Diodem” means Diodem, LLC, a California limited liability company.

     “Diodem Group” means, individually and collectively, Diodem, Colette Cozean, Lares
Research, Craig Lares, Patrick Day, and Dovel & Luner.

     “Colette Cozean” means Colette Cozean, an individual residing in California and the managing
member of Diodem.

     “Lares Research” means Lares Research, a California corporation that is a member of Diodem.

     “Craig Lares” means Craig Lares, an individual residing in California and the President of
Lares Research.

     “Patrick Day” means Patrick Day, an individual residing in California and a member of Diodem.

     “Dovel & Luner” means Dovel & Luner, LLP, a limited liability partnership and counsel for
Diodem in both the Patent Lawsuit and the Contract Lawsuit.

2. RELEASES

     2.1 Release by the Diodem Group. In consideration of the promises and covenants
herein, the sufficiency of which is hereby acknowledged, the Diodem Group, and each of them,
separately and collectively, completely, absolutely and forever release and discharge (i) the
Biolase Parties, and each of them, and (ii) (but only insofar as they were or are acting in their
capacities as such) their past and present directors, managers, officers, shareholders, agents,
employees, subsidiaries, affiliates, attorneys at law, attorneys in fact, associates, consultants,
insurers, agents, representatives, successors and assigns, heirs, executors, administrators,
beneficiaries, and devisees, as well as any person acting by, through, under, or in concert with
each of them or any of them, and each of them, separately and collectively, of and from any and all
claims, demands, and causes of action of every kind, nature, character and description whatsoever,
whether known or unknown, however arising, fixed or contingent, whether based on tort, contract or
any other theory, including securities law, which the Diodem Group has or may have as of the
Effective Date that directly or indirectly arise out of, or are in any manner related to, the
subject matter (and defense) of the Contract Lawsuit (including without limitation claims relating
to the licensing and settlement negotiations with Hoya and Lumenis, the representations and
warranties made in Section 9 of the Registration Rights

 - 2 - 

 

Agreement, and Biolase’s alleged failure to
register stock issued to Diodem pursuant to the Definitive Agreement and the Registration Rights
Agreement), as well as the costs, expenses or attorneys’ fees incurred in connection with the
Contract Lawsuit or drafting or negotiation of this Agreement (hereinafter all collectively
referred to as the “Released Claims”).

     2.2 Release by the Biolase Parties. In consideration of the promises and covenants
herein, the sufficiency of which is hereby acknowledged, the Biolase Parties, and each of them,
separately and collectively, completely absolutely and forever release, waive, discharge, and
relinquish (i) the Diodem Group, and each of them, and (ii) (but only insofar as they were or are
acting in their capacities as such) their past and present directors, managers, officers,
shareholders, agents, employees, subsidiaries, affiliates, attorneys at law, attorneys in fact,
associates, consultants, insurers, agents, representatives, successors and assigns, heirs,
executors, administrators, beneficiaries, and devisees, as well as any person acting by, through,
under, or in concert with each of them or any of them, and each of them, separately and
collectively, of and from any and all claims, demands, and causes of action of every kind, nature,
character and description whatsoever, whether known or unknown, however arising,
fixed or contingent, whether based on tort, contract or any other theory, which the Biolase Parties
have or may have as of the Effective Date that directly or indirectly arise out of, or are in any
manner related to, the subject matter (and filing) of the Contract Lawsuit (including without
limitation claims relating to the licensing and settlement negotiations with Hoya and Lumenis, the
representations and warranties made in Section 9 of the Registration Rights Agreement, and
Biolase’s alleged failure to register stock issued to Diodem pursuant to the Definitive Agreement
and the Registration Rights Agreement), as well as the costs, expenses or attorneys’ fees incurred
in connection with the Contract Lawsuit or drafting or negotiation of this Agreement.

     2.3 Section 1542. The parties hereby acknowledge and represent that they have been
informed by their attorneys of, and are personally familiar with, Section 1542 of the Civil Code of
the State of California, which provides as follows:

“A general release does not extend to claims which the creditor does not know
or suspect to exist in his or her favor at the time of executing the release,
which if known by him or her must have materially affected his settlement
with the debtor.”

Each of the parties understands it may hereafter discover facts in addition to or different from
those that any of them now knows or believes to be true related to the Released Claims but each
party hereby waives and relinquishes any and all rights and benefits under Section 1542 of the
Civil Code, if any, as presently in effect and as amended from time to time hereafter, and under
any successor thereto, with respect to the matters released herein.

     2.4 Covenant not to sue. The Diodem Group, and each of them, covenants and agrees
that they will not file, initiate, commence, institute, maintain, prosecute, aid, assist or
participate in any way in any action at law, suit in equity or other proceeding

 - 3 - 

 

(whether
administrative, judicial or otherwise) against the Biolase Parties, or any of their officers,
employees or agents, for any matter included within the Released Claims. The Biolase Parties may
seek a temporary restraining order or preliminary or permanent injunction against any violation of
this paragraph 2.4. The Parties agree that monetary damages would be inadequate to remedy any
violation of this paragraph 2.4.

     2.5 Definitive Agreement still in force. The parties agree that (a) except to the
extent inconsistent with the releases and covenants set forth in Sections 2.1 though 2.4 above, all
terms, obligations, and promises set forth in the Definitive Agreement and its ancillary agreements
(including without limitation the obligations and promises regarding the sharing of royalty
payments from third parties set forth in Section 6 of the Definitive Agreement) remain in full
force and effect and are unmodified by this Agreement, and (b) the Diodem Group and the Biolase
Parties are not releasing or waiving any claims that may arise against the other for breaches of
the Definitive Agreement occurring after the Effective Date.

     2.6 Further Litigation. In the event that, subsequent to the Effective Date, any
member of the Diodem Group files a lawsuit against any of the Biolase Parties asserting claims
relating to an alleged breach or violation of the Definitive Agreement or the Registration Rights
Agreement, where such breach or violation is alleged to have occurred prior to the
Effective Date then (i) the Diodem Group shall forfeit its right to receive the final payment due
under Section 3(d) of this Agreement if such payment has not already been made or (ii), if such
final payment has already been made, any potential recovery obtained or damages alleged by the
Diodem Group (or its member(s)) in such lawsuit shall be reduced by the amount of $150,000 (one
hundred and fifty thousand dollars).

3. PAYMENT

     Biolase shall make the following cash payments to Diodem:

     (a) No later than October 15, 2008, Biolase shall pay Diodem the sum of four hundred
seventy-five thousand dollars ($475,000) (the “Initial Payment”);

     (b) No later than February 1, 2009, Biolase shall pay Diodem the additional sum of one
hundred and fifty four thousand and two hundred dollars ($154,200). If Biolase elects
to make this payment prior to February 1, 2009, the payment will be reduced by the amount equal to
$28.80 multiplied by the number of days the payment is early;

     (c) No later than August 1, 2009, Biolase shall pay Diodem the additional sum of one
hundred and fifty nine thousand and four hundred and six dollars ($159,406). If
Biolase elects to make this payment prior to August 1, 2009, the payment will be reduced by the
amount equal to $28.80 multiplied by the number of days the payment is early; and

 - 4 - 

 

     (d) No later than February 1, 2010, Biolase shall pay Diodem the additional sum of one
hundred and ninety two thousand and one hundred fifty dollars ($192,150). If Biolase
elects to make this payment prior to February 1, 2010, the payment will be reduced by the amount
equal to $33.56 multiplied by the number of days the payment is early.

     All payments will be made by bank wire to the following account of Diodem (or such other
account as is specified in writing by Diodem):

Union Bank of California

25276 Marguerite Pkwy

Mission Viejo, CA 92692

Tel. (949) 768-8100

Routing number: 122000496

Account holder: Diodem LLC

Account no.: 2072156074

The Diodem Group has agreed among them as to the division of the cash payments. The Biolase
Parties shall have no obligation or right to apportion or divide the cash payments among the Diodem
Group and no obligation to pay any taxes or expenses associated with the Diodem Group’s receipt of
the cash payments made under this Agreement.

4. DISMISSAL

     Within three (3) business days of the receipt of the Initial Payment, Diodem will dismiss with
prejudice the Contract Lawsuit, with the dismissal specifying that (a) the parties are to bear
their own costs and attorneys’ fees, and (b) the Superior Court of California for the County of Los
Angeles will retain jurisdiction to enforce the terms of this Agreement.

5. REPRESENTATIONS AND WARRANTIES

     5.1 Representations by the Diodem Group. Each of the parties that comprise the Diodem
Group represents and warrants that (a) it has not assigned any of the claims or causes of action
asserted in the Contract Lawsuit or otherwise released in Section 2.1 above to any other party,
other than to Diodem (as asserted in the complaint in the Contract Lawsuit), and (b) it (alone or
together with the other parties comprising the Diodem Group) has the excusive authority to bring
the claims asserted in the Contract Lawsuit and to receive the consideration set forth in Section 3
above, and has the necessary power and authority to execute this Agreement and to make the releases
set forth in Section 2.1 above, and that no other person or entity has claimed or now claims any
interest in the subject of the Contract Lawsuit or this Agreement.

     5.2 Representations by the Biolase Parties. The Biolase Parties represent and warrant
that (a) they have not assigned any of the claims or causes of action released in

 - 5 - 

 

Section 2.2 above
to any other party, and (b) they have the necessary power and authority to enter into this
Agreement and to make the releases set forth in Section 2.2 above.

6. GENERAL PROVISIONS

     6.1 Entire Agreement; Counterparts. Except as noted in Section 2.5 above, this
Agreement constitutes the entire agreement between the parties relating to the subject matter
hereof and supersedes all previous agreements, practices or courses of dealings between the
parties, whether written or oral, relating to the subject matter hereof. The Parties hereto
warrant that no promise, inducement or agreement not expressed herein has been made to them in
connection with this Agreement. This Agreement may be executed in counterparts with the same force
and effect as if each of the signatories had executed the same instrument.

     6.2 Assignment. This Agreement shall be binding upon, and inure to the benefit of,
the Parties’ successors and assigns. There shall be no third party beneficiaries, either express
or implied, to this Agreement except to the extent set forth in Section 2.1(ii) and 2.2(ii) above.

     6.3 Waivers; Amendments; Supplements. No waiver by any party of a breach of any
covenant or condition of this Agreement by another party shall be construed to be a waiver of any
succeeding breach of the same or any other covenant or condition. Except as otherwise expressly
provided herein, this Agreement may not be changed or amended except by a writing expressly
referring to this Agreement signed by all the parties.

     6.4 Governing Law. This Agreement shall be governed and construed in accordance with
the laws of the State of California, without regard to such law’s principles of conflicts of law,
and the parties agree that it is executed and delivered in that State.

     6.5 Forum; Attorneys Fees. The parties agree that any legal action or other legal
proceeding to resolve any dispute involving or arising out of any alleged breach of this Agreement
shall be exclusively conducted in the Superior Court of California for the County of Los Angeles.
The prevailing party in any such legal action or proceeding shall be entitled to recover its
reasonable costs and expenses, including attorneys’ fees, in connection with the dispute.

     6.6 No admission of liability or wrongdoing. The Diodem Group and the Biolase Parties
agree that the payment of the sums specified herein and the execution of this Agreement are done
entirely for the purpose of compromise and settlement of disputed claims. Neither the payment of
such sums nor the compromise and settlement of the Released Claims shall be construed as an
admission of liability on the part of the Biolase Parties, by whom liability is expressly denied.
Nothing contained in this Agreement may be used or construed by any person as an admission of
liability in any

 - 6 - 

 

amount whatsoever to any person. This Agreement shall not be offered or received
in evidence in any action or proceeding in any court or other tribunal as an admission or
concession of liability or wrongdoing of any nature on the part of Diodem Group or the Biolase
Parties, including any employee or agent thereof. In addition, the Diodem Group disputes that
Diodem lacks standing to assert any of the claims pleaded in the Contract Lawsuit and provides
releases and representations from the parties other than Diodem solely in an effort to address the
concerns of the Biolase Group and to reach a compromise of the lawsuit.

     6.7 Confidentiality. This Agreement and its terms shall be maintained in confidence
by each of the Parties, except to the extent the disclosure of this Agreement, or the terms or
provisions therein, is required pursuant to the rules or regulations of the SEC, generally accepted
accounting principles applicable to Biolase or Diodem, as the case may be, or otherwise pursuant to
court order or law.

     6.8 Severability. If any provision of this Agreement should be held to be void or
unenforceable, such provision or part thereof shall be treated as severable, leaving valid the
remainder of such agreement.

     6.9 Advice of Counsel. The Diodem Group each acknowledge that, in making their
decision to settle this matter, they have relied upon the advice of their own counsel; that they
have been fully advised by said attorneys with respect to their rights and obligations with respect
to the execution of this Agreement; that they are entering into this Agreement freely and
voluntarily and not under any threat of coercion or duress; and that they hereby authorize and
direct said attorney to take such action as may be necessary or appropriate to terminate the
Contract Lawsuit with prejudice.

     6.10 Interpretation. The parties agree that this Agreement was jointly drafted by the
parties and their counsel and further agree that no provision of this Agreement is to be
interpreted for or against either party based on any assertion that it was drafted by that party or
its counsel.

     6.11 Notices. All notices, demands, requests, approvals, consents or other
communications relating to this Agreement shall be in writing and shall be deemed to have been
given: (i) when delivered in person or by courier; (ii) upon confirmation of receipt when sent by
certified mail, return receipt requested; (iii) upon confirmation by the recipient of receipt of
e-mail to the address set forth below; or (iv) upon receipt when sent by reputable private
international courier with established tracking capability (such as DHL, FedEx, or UPS), postage
pre-paid, and addressed to the noticed party at the address set forth below, or such other address
as a party may specify by written notice to the other.

	 	 	 
	If to the Diodem Group:

	 	 If to Biolase or BL Acquisition II:
	 
	 	 
	Attn: Colette Cozean, Ph.D.

	 	Attn: Chief Financial Officer
	Diodem, LLC

	 	Biolase Technology, Inc.

 - 7 - 

 

	 	 	 
	21581 Midcrest Drive

	 	4 Cromwell
	Lake Forest, CA 92630

	 	Irvine, CA 92618
	ccozean@cox.net
	 	 

     IN WITNESS WHEREOF, the Parties hereto, intending to be legally bound hereby, have each caused
its duly authorized representative to execute and deliver this Agreement under seal of the
Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	Diodem, LLC	 	 	 	Biolase Technology, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Colette Cozean
	 	 	 	By:
	 	/s/ Jake St. Philip	 	 
	 

	 	 

Name: Colette Cozean, PhD
	 	 	 	 	 	 

Name: Jake St. Philip
	 	 
	 

	 	Title: Managing Director
	 	 	 	 	 	Title: CEO	 	 
	 

	 	Date: 9/30/08
	 	 	 	 	 	Date:10/1/08	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Colette Cozean, Ph.D., an individual	 	 	 	BL Acquisition II, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	/s/ Colette Cozean
	 	 	 	By:
	 	/s/ Jake St. Philip	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Date: 9/30/08
	 	 	 	 	 	Name: Jake St. Philip	 	 
	 

	 	 	 	 	 	 	 	Title: CEO	 	 
	 

	 	 	 	 	 	 	 	Date: 10/1/08	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Patrick Day, an individual	 	 	 	Dovel & Luner, LLP	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	/s/ Patrick Day
	 	 	 	By: 	 	/s/ Greg Dovel	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Date: 10/9/08
	 	 	 	 	 	Name: Greg Dovel	 	 
	 

	 	 	 	 	 	 	 	Title: Partner	 	 
	 

	 	 	 	 	 	 	 	Date:10/1/08	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Lares Research	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Craig S. Lares	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	Name: Craig S. Lares	 	 	 	 	 	 	 	 
	 

	 	Title: President	 	 	 	 	 	 	 	 
	 

	 	Date: 10/1/08	 	 	 	 	 	 	 	 

 - 8 - 

 

	 	 	 	 	 	 	 	 	 	 	 
	Craig Lares, an individual	 	 	 	 	 	 	 	 
	 
	 

	 	/s/ Craig S. Lares	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	Date: 10/1/08	 	 	 	 	 	 	 	 

 - 9 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]